Disease Research

 
Stock Quotes for Disease Research top ^
  • Industry: Diagnostics & Research
  • Sector: Healthcare
Sign-up for htds investment picks

 
News Articles for Disease Research top ^
2015/2/27
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) joins the European Organization for Rare Diseases (EURORDIS), the National Organization for Rare Disorders (NORD) and rare disease patient and healthcare advocates around the world in recognizing and supporting Rare Disease Day 2015.
Sign-up for Alexion Joins Patient Organizations Worldwide in Support of International Rare Disease Day 2015 investment picks
2015/2/23
ZUG, Switzerland , February 23, 2015 /PRNewswire/ -- New awareness materials posted on Shire.com highlight the challenging diagnosis journey many people with a rare disease face Average time to diagnosis for rare diseases is around 5 years and typically involves 2-3 misdiagnoses [1 ],[ 2 ] An accurate diagnosis may be the first step to improving the care for those living with a rare disease [1 ],[ 3 ] Shire plc (LSE: SHP, NASDAQ: SHPG) today announced its support of Rare Disease Day 2015 by calling for improvements in the journey to diagnosis for those living with a rare disease.
Sign-up for Shire Calls for Improved Rare Disease Diagnosis on Rare Disease Day 2015 investment picks
2015/2/26
Pfizer Inc. (NYSE: PFE) announced today that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend serogroup B meningococcal vaccination to help protect individuals at increased risk.
Sign-up for CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk investment picks
2014/12/8
Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.
Sign-up for Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform investment picks
2015/1/29
RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing RHB-104 Phase III Crohn's disease development program Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients; Based of FDA's feedback, RedHill and Quest Diagnostics plan to commence a study to assess the clinical utility of the diagnostic test in Q2-Q3/2015 A protocol amendment for the ongoing Phase III study of RHB-104 in Crohn's disease has been filed with FDA and is expected to significantly increase the number of patients eligible to enroll in this study The RHB-104 Phase III MAP US study for Crohn's disease is one of RedHill's three ongoing Phase III studies in the U.S. with three of its drug candidates targeting gastrointestinal diseases TEL-AVIV, Israel, Jan.
Sign-up for RedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting investment picks
2015/2/12
Genzyme , a Sanofi company, today presented data from its Phase 1b clinical study at the Lysosomal Disease Network’s WORLD Symposium 2015 in Orlando, Fla.
Sign-up for Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network’s WORLD Symposium 2015 investment picks
2015/2/27
LEXINGTON, Mass.
Sign-up for Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 investment picks
2014/12/16
Pivotal Phase 3 Trial Met Primary and Multiple Key Secondary Efficacy Endpoints; Favorable Safety and Tolerability Demonstrated ARC-HD Trial Shows Successful Maintenance of Chorea Control After Switch to SD-809 NDA Submission Planned by Mid-2015 Conference Call Scheduled for 4:30 PM ET / 1:30 PM PT Today LA JOLLA, Calif., Dec.
Sign-up for Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease investment picks
2015/1/26
CRANBURY, N.J., Jan.
Sign-up for Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium investment picks
2014/12/8
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase III program with NUPLAZID™ (pimavanserin) for Parkinson’s disease psychosis (PDP) at the 10 th Annual International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders held from December 5-7 in Nice, France.
Sign-up for ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders investment picks
2015/2/23
NOVATO, Calif., Feb.
Sign-up for Raptor Pharmaceutical to Observe International Rare Disease Day Through Global Awareness Programs investment picks
2015/2/13
Heat Stable Ricin Toxin Vaccine Elicits Strong Immune Responses and Protects Animals from Ricin Intoxication PRINCETON, N.J. , Feb.
Sign-up for Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC investment picks
2015/2/12
Genzyme , a Sanofi company, today reported extension study data from its Phase 3 ENGAGE and ENCORE studies of Cerdelga ® (eliglustat), a first-line oral therapy approved by the FDA and the European Commission for the treatment of certain adults with Gaucher disease type 1.
Sign-up for Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga® (eliglustat) at Lysosomal Disease Network’s WORLD Symposium 2015 investment picks
2014/12/29
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted both orphan drug designation and rare pediatric disease designation for Ignyta’s lead product candidate entrectinib for the treatment of neuroblastoma.
Sign-up for Ignyta Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA for Entrectinib for the Treatment of Neuroblastoma investment picks
2015/1/8
Covidien plc (NYSE:COV) today announced it has received CE Mark approval for its Stellarex™ drug-coated angioplasty balloon (DCB). The Stellarex™ DCB is used to restore and maintain blood flow to the arteries of the leg in patients with peripheral arterial disease (PAD). The Stellarex™ DCB is inserted into the diseased artery and inflated to open the vessel and restore blood flow, while a drug called paclitaxel is deposited onto the vessel wall to prevent the reoccurrence of new blockages.
Sign-up for Covidien’s Stellarex™ Drug-Coated Angioplasty Balloon Receives CE Mark to Treat Peripheral Arterial Disease Patients investment picks
2014/12/10
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson’s disease (PD). OFF episodes are characterized by a re-emergence of PD symptoms such as tremor, muscle stiffness and impaired ability to move.
Sign-up for Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson’s Disease investment picks
2015/2/2
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it has initiated a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases.
Sign-up for Alnylam Initiates Phase 1/2 Clinical Trial for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases investment picks
2015/2/11
SGX943 in combination with antibiotics increases survival in an acute, lethal pneumonic model PRINCETON, N.J. , Feb.
Sign-up for Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Disease Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Disease Management  |  Next: Display Technology